| Drug Type Bispecific T-cell Engager (BiTE) | 
| Synonyms QL 335, QL335 | 
| Target | 
| Action stimulants, inhibitors | 
| Mechanism CD3 stimulants(T cell surface glycoprotein CD3 stimulants), LY6G6D inhibitors(lymphocyte antigen 6 family member G6D inhibitors) | 
| Therapeutic Areas | 
| Active Indication | 
| Inactive Indication- | 
| Originator Organization | 
| Active Organization | 
| Inactive Organization- | 
| License Organization- | 
| Drug Highest PhasePhase 1 | 
| First Approval Date- | 
| Regulation- | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Colorectal Cancer | Phase 1 | - | - | 






